loading page

Clinical manifestation of supra-large range non-perfusion area diabetic retinopathy: a specific severe diabetic retinopathy
  • +2
  • Nianting Tong,
  • Liangyu Wang,
  • Huimin Gong,
  • Lin Pan,
  • Zhanyu Zhou
Nianting Tong
Qingdao Municipal Hospital Group
Author Profile
Liangyu Wang
Qingdao Municipal Hospital Group
Author Profile
Huimin Gong
Qingdao Municipal Hospital Group
Author Profile
Lin Pan
Qingdao Municipal Hospital Group
Author Profile
Zhanyu Zhou
Qingdao Municipal Hospital Group

Corresponding Author:[email protected]

Author Profile

Abstract

Objective: The aim of this study was to describe the clinical manifestation of a specific type of diabetic retinopathy (DR), supra-large range non-perfusion area diabetic retinopathy (SLRNPA DR). Methods: This is a retrospective consecutive case series study. 260 eyes from 236 patients who suffered from diabetic retinopathy and underwent pars plana vitrectomy in the department of ophthalmology, Qingdao Municipal Hospital from February 2016 to June 2019 were enrolled. Fundus fluorescein angiography (FFA) was used after surgery to determine whether it was SLRNPA DR or non-SLRNPA DR. The demographics and relevant clinical data of these patients were carefully collected. Results: In this cohort, 41 eyes from 22 patients were diagnosed as SLRNPA DR, which was 15.77% of all eyes. When compared with non-SLRNPA DR patients, SLRNPA DR patients were more male, younger age and onset, and more likely to have history of smoking, have other comorbidities, have higher HbA1c. As for SLRNPA DR eyes, higher probability of occurrence of neovascular glaucoma (NVG) and diabetic keratopathy (DK) was found. There eyes were more likely to need anti-VEGF therapy before surgery, more likely to need silicon oil or gas tamponade during the surgery, and more likely to be suffered from persistent corneal epithelial erosion (PCEE) and recurrence of NVG. Conclusions: SLRNPA DR is a specific type of DR, which might be more severe than common kinds of DR. We need pay more attention to SLRNPA DR during our clinical process.